PECAM1 and glioblastoma: In line with this finding, serum Ang‐2 levels remained unchanged in patients before and after bevacizumab therapy, despite a 66% decrease in the number of CD31+ endothelial cells, which are the cellular source of Ang‐2 in GBM.